Table 1.
Characteristics of Study Group of Breast Cancer Patients
| |
n (%) |
|
|
|---|---|---|---|
| Tumor characteristic | Premenopausal patients N = 53 | Postmenopausal patients N = 109 | p-Value |
| Tumor size | |||
| <20 mm | 30 (56.7) | 37 (33.8) | 0.006 |
| 20–50 mm | 21 (39.6) | 66 (60.5) | 0.01 |
| >50 mm | 2 (3.7) | 6 (5.7) | 0.72 |
| Grade | |||
| Low | 4 (7.5) | 7 (6.4) | 1.00 |
| Medium | 49 (92.5) | 97 (89.0) | 0.58 |
| High | 0 (0.0) | 5 (4.6) | — |
| ER status | |||
| Positive | 31 (68.9) | 59 (67.0) | 0.82 |
| Negative | 14 (31.1) | 29 (33.0) | |
| Unknown | 8 | 21 | |
| PR status | |||
| Positive | 33 (73.3) | 48 (55.2) | 0.04 |
| Negative | 12 (26.7) | 39 (44.8) | |
| Unknown | 8 | 22 | |
| HER2/neu status | |||
| Negative | 31 (81.6) | 61 (81.3) | 0.82 |
| Positive | 7 (18.4) | 14 (18.7) | |
| Unknown | 15 | 34 | |
| Molecular subtypes | |||
| Luminal | 30 (81.1) | 51 (68.9) | 0.26 |
| HER2-enriched | 3 (8.1) | 7 (9.5) | 1.00 |
| Triple-negative | 4 (10.8) | 16 (21.6) | 0.19 |
| Unknown | 16 | 35 | |
| Lymph node metastases | |||
| − | 36 (67.9) | 66 (60.6) | 0.36 |
| + | 17 (32.1) | 43 (39.4) | |
| Hematogenic metastases | |||
| − | 41 (77.4) | 96 (88.1) | 0.08 |
| + | 12 (22.6) | 13 (11.9) | |
| Recurrence | |||
| − | 46 (86.8) | 102 (93.6) | 0.23 |
| + | 7 (13.2) | 7 (6.4) | |
n, number of patients presenting with a specific tumor characteristic; N, total number of patients in group of pre- or postmenopausal patients; ER, estrogen receptor; PR, progesterone receptor; −, absent; +, present.